EMA/102949/2013

European Medicines Agency decision

P/0062/2013

of 26 March 2013

on the acceptance of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0062/2013

of 26 March 2013

on the acceptance of a modification of an agreed paediatric investigation plan for ambrisentan (Volibris), (EMEA-000434-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/224/2009 issued on 4 November 2009,

Having regard to the application submitted by Glaxo Group Limited on 19 November 2012 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 February 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ambrisentan (Volibris), film-coated tablet, powder for oral solution, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Glaxo Group Limited, Greenford Road, Greenford, Middlesex, UB6 0HE London, United Kingdom.

Done at London, 26 March 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/817611/2012

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000434-PIP01-08-M01

Scope of the application

Active substance(s):

Ambrisentan

Invented name:

Volibris

Condition(s):

Primary and secondary pulmonary hypertension

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Powder for oral solution

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Glaxo Group Limited

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Glaxo Group Limited submitted to the European Medicines Agency on 19 November 2012 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/224/2009 issued on 4 November 2009.

The procedure started on 12 December 2012.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 8 February 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of pulmonary arterial hypertension

The waiver applies to:

- Children less than one year of age;
- for film-coated tablet and powder, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of pulmonary arterial hypertension

2.2. Indication(s) targeted by the PIP

Idiopathic (IPAH) and familial (FPAH) pulmonary hypertension; Associated pulmonary hypertension (APAH).

2.3. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age.

2.4. Pharmaceutical form(s)

Film-coated tablet, powder for oral solution.

2.5. Measures

Area	Number of measures	Description
Quality	2	Measure 1: Development of film coated tablets 2.5 mg for oral use. Measure 2: Development of oral powder in a single dose sachet for oral use.
Non-clinical	2	Measure 3: 2-week juvenile animal study to determine tolerability and toxicokinetics of ambrisentan. Measure 4: 8-week juvenile animal study to determine oral toxicology and toxicokinetic of ambrisentan including an 8 weeks recovery period.
Clinical	3	Measure 5: 24 weeks randomized, open label, multi-centre, comparative trial to evaluate safety, efficacy and population PK of ambrisentan low and high dose for the treatment of children from 8 years of age to less than 18 years of age with Pulmonary Arterial Hypertension. Measure 6: Bioavailability study to compare the pharmacokinetic profile of the dry powder in a single dose sachet for oral use with the existing film coated tablets of ambrisentan. Measure 7: 24 weeks randomized, open label, multi-centre, comparative trial

Area	Number of measures	Description
		to evaluate safety, efficacy and PK of ambrisentan low and high dose for the treatment of children from 1 year of age to less than 8 years of age with Pulmonary Arterial Hypertension.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2016
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of pulmonary arterial hypertension

   Authorised indications: treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.

Authorised pharmaceutical formulation(s):

Film-coated tablet.

Authorised route(s) of administration:

Oral use.